Search research articles
Contact Us
Filters
Showing results (301-310 of 365) with videos related to
Page
of 37
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 18, 2022
Venetoclax Plus Gilteritinib for <i>FLT3</i>-Mutated Relapsed/Refractory Acute Myeloid Leukemia
Naval Daver, Alexander E Perl, Joseph Maly, et al.
The Journal of Clinical Investigation
|
July 28, 2022
Bone marrow-confined IL-6 signaling mediates the progression of myelodysplastic syndromes to acute myeloid leukemia
Yang Mei, Kehan Ren, Yijie Liu, et al.
European Heart Journal
|
May 23, 2012
Multidisciplinary care of patients receiving cardiac resynchronization therapy is associated with improved clinical outcomes
Robert K Altman, Kimberly A Parks, Christopher L Schlett, et al.
British Journal of Haematology
|
March 18, 2014
F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma
Ryan D Gentzler, Andrew M Evens, Alfred W Rademaker, et al.
The Lancet. Haematology
|
March 29, 2023
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study
Guillermo Garcia-Manero, Aaron D Goldberg, Eric S Winer, et al.
Blood Advances
|
May 29, 2024
Air pollutant impact on disease characteristics and outcomes in patients with acute myeloid leukemia
Andrew Palmer, Garth Rauscher, Ivy Abraham, et al.
Blood
|
December 28, 2018
Identification and targeting of novel CDK9 complexes in acute myeloid leukemia
Elspeth M Beauchamp, Sameem M Abedin, Sara G Radecki, et al.
Blood Advances
|
December 6, 2025
Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure
Kuo-Kai Chin, Brian J Ball, Yasmin Abaza, et al.
Blood Cancer Journal
|
May 31, 2022
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
Alexander E Perl, Naoko Hosono, Pau Montesinos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 13, 2021
Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin
Alan F List, Zhuoxin Sun, Amit Verma, et al.
Page
of 37
Search research articles
Search
Showing results (301-310 of 365) with videos related to
Sort By:
Page
of 37
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 18, 2022
Venetoclax Plus Gilteritinib for <i>FLT3</i>-Mutated Relapsed/Refractory Acute Myeloid Leukemia
Naval Daver, Alexander E Perl, Joseph Maly, et al.
The Journal of Clinical Investigation
|
July 28, 2022
Bone marrow-confined IL-6 signaling mediates the progression of myelodysplastic syndromes to acute myeloid leukemia
Yang Mei, Kehan Ren, Yijie Liu, et al.
European Heart Journal
|
May 23, 2012
Multidisciplinary care of patients receiving cardiac resynchronization therapy is associated with improved clinical outcomes
Robert K Altman, Kimberly A Parks, Christopher L Schlett, et al.
British Journal of Haematology
|
March 18, 2014
F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma
Ryan D Gentzler, Andrew M Evens, Alfred W Rademaker, et al.
The Lancet. Haematology
|
March 29, 2023
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study
Guillermo Garcia-Manero, Aaron D Goldberg, Eric S Winer, et al.
Blood Advances
|
May 29, 2024
Air pollutant impact on disease characteristics and outcomes in patients with acute myeloid leukemia
Andrew Palmer, Garth Rauscher, Ivy Abraham, et al.
Blood
|
December 28, 2018
Identification and targeting of novel CDK9 complexes in acute myeloid leukemia
Elspeth M Beauchamp, Sameem M Abedin, Sara G Radecki, et al.
Blood Advances
|
December 6, 2025
Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure
Kuo-Kai Chin, Brian J Ball, Yasmin Abaza, et al.
Blood Cancer Journal
|
May 31, 2022
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
Alexander E Perl, Naoko Hosono, Pau Montesinos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 13, 2021
Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin
Alan F List, Zhuoxin Sun, Amit Verma, et al.
Page
of 37